Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N7O7S3.Na.H.7H2O |
Molecular Weight | 667.664 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].O.O.O.O.O.O.O.[Na+].[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C([O-])=O)OC)C([O-])=O
InChI
InChIKey=QCIJKKRQPRMHOX-CVQRGOFGSA-M
InChI=1S/C16H21N7O7S3.Na.7H2O/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26;;;;;;;;/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28);;7*1H2/q;+1;;;;;;;/p-1/t8-,14-,16+;;;;;;;;/m1......../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H19N7O7S3 |
Molecular Weight | 517.56 |
Charge | -2 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.toku-e.com/Cefminox-sodium-P646.aspx and http://www.ncbi.nlm.nih.gov/pubmed/9517922
Curator's Comment: Description was created based on several sources, including http://www.toku-e.com/Cefminox-sodium-P646.aspx and http://www.ncbi.nlm.nih.gov/pubmed/9517922
Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. It is indicated in treatment of the following infections caused by sensitive bacteria:
1. Respiratory infections: Amygdalitis, circumtonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (in fection), secondary infections of chronic respiratory diseases, pneumonia, and pulmonary suppuration;
2. Infection in urinary system: Nephropyelitis, cystitis;
3. Infections in abdominal cavity: Cholecystitis' angiocholitis'peritonitis;
4. Infections in pelvic cavity: Pelvic peritonitis, adnexitis, intrauterine infection, inflammation in pelvic dead space, and parametritis;
5. Septicaemia.
Originator
Sources: http://docslide.us/documents/pp8launch19951997.html
Curator's Comment: Sankyo Launched cefminox in 1995
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/25672407 |
|||
Target ID: map00550 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. | 1994 Jan |
|
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds. | 1998 Mar |
|
Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus. | 2000 Jan 15 |
|
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study. | 2014 |
|
In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China. | 2015 |
Patents
Sample Use Guides
Administration only for intravenous injection or intervenous drop injection. For intravenous injection: Cefminox sodium 1g (valence) can be dissolved in 200ml water for injection, and 5~10% glucose or 0.9% sodium chloride injection. For intervenous drop injection: Cefminox sodium 1g (valence) can be dissolved in 100~500ml 5~10% glucose or 0.9% sodium chloride injection. A drop innjection for 1~2 hours. Recommended dose for adults: 1g (valence) to be administrated twice a day; Adjusted according to the age and symptoms; In septicaemia, and refractory or severe infections, a total daily dosage of 6g (valence) is divided into 3~4 administrations. Recommended dose for children: 20mg (valence)/kg (body weight) to be administrated 3~ 4 times a day.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/25672407
The MIC50 and MIC90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:35:28 GMT 2023
by
admin
on
Sat Dec 16 05:35:28 GMT 2023
|
Record UNII |
KZ89N378LQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000047535
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
1351813-81-4
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
m3198
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID50159274
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
DBSALT001119
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
KZ89N378LQ
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
31371
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY | |||
|
45356840
Created by
admin on Sat Dec 16 05:35:28 GMT 2023 , Edited by admin on Sat Dec 16 05:35:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |